Device and method for direct drug infusion

Abstract

An apparatus and method are provided for direct infusion of a medication from a vial to a patient. Also provided is a mobile hanger label to be adhered to and supported by the vial to facilitate direct infusion of a medication, such as one or more pharmaceuticals, biotechnology drugs, and / or biological agents, from the vial to the patient. Further, a method is provided in which the medication contained in the vial with the mobile hanger label can be directly infused through a primed infusion line at a rapid infusion rate. At the end of administration, a saline flush is added to flush the infusion line, thereby reducing the amount of medication remaining in the line.

Description

[0001] Cross-referencing of related patent applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 966,495, filed January 27, 2020, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present subject matter described herein generally relates to drug infusion from a bottle to a patient. More specifically, the present subject matter relates to an apparatus and method for direct drug infusion from a bottle to a patient. Background Technology

[0004] The infusion of medications, such as one or more pharmaceutical products, biotechnology drugs, and / or biologics, may involve administering the medication to a patient via intravenous infusion. One or more healthcare professionals may be responsible for intravenous administration, which may include, for example, dosage preparation procedures and patient preparation procedures, to administer the medication to a patient via intravenous infusion. Summary of the Invention

[0005] The current topic encompasses various aspects of direct drug infusion from vials to patients, thereby streamlining the workflow for healthcare professionals and reducing the time patients spend receiving medication.

[0006] This invention simplifies the workflow for healthcare professionals by allowing undiluted liquid drug solutions to be administered directly intravenously (IV) from their main container. It eliminates the need for dilution into the IV bag before administration and results in shorter infusion times. Therefore, it provides healthcare systems with a more convenient and faster IV administration option. It significantly reduces infusion time and thus promises to improve the patient experience.

[0007] According to various aspects disclosed herein, an apparatus is provided. The apparatus includes a tag. The tag includes a back surface region and a front surface region opposite to the back surface region. A portion of the back surface region and the opposite portion of the front surface region of the tag include a movable bracket. The movable bracket causes movement from a first position to a second position. In the first position, the movable bracket is at least substantially aligned with the remainder of the back surface region and the opposite remainder of the front surface region. In the second position, the movable bracket is at least partially separated from the remainder of the back surface region and the opposite remainder of the front surface region.

[0008] In some variations, one or more of the features disclosed herein, including the following features, may optionally be included in any feasible combination. In some variations, the remainder of the back surface region of the label may be configured to adhere to an outer wall of the bottle. In some variations, the label may comprise a flexible material. In some variations, the back surface region may comprise a portion of the back surface region and the remainder of the back surface region, and the front surface region may comprise an opposite portion of the front surface region and the opposite remainder of the front surface region. In some variations, the label may further comprise a perforation extending through the back surface region and the front surface region, and the perforation may define at least a portion of the periphery of a movable hanger. In some variations, the perforation may be configured to at least partially separate the movable hanger from the remainder of the back surface region and the opposite remainder of the front surface region. In some variations, the movable hanger may be configured to move along the perforation from a first position to a second position. In some variations, the movable hanger in the second position may include an annular structure, and the annular structure may include two fixed ends. In some variations, when the label is affixed to the bottle, the movable hanger in the second position may be configured to support the bottle from the dispensing rack. In some variations, the movable hanger in the second position may be positioned such that the bottle hangs substantially downward away from the dispensing rack. In some variations, the label may include text on a front surface area, and the text may be upside down, face up, or a combination thereof when the bottle is suspended substantially downward. In some variations, the movable hanger in the second position may be configured to support a weight of up to about 500 kg for the bottle. In some variations, the length of the label may be between about 75 mm and about 100 mm. In some variations, the height of the label may be between about 30 mm and about 40 mm. In some variations, the width of the movable hanger may be between about 5 mm and about 7 mm.

[0009] In another related aspect, a method is provided. The method includes infusing a first volume of physiological saline into an infusion line via an infusion pump; removing a cap from a bottle containing the medication, wherein the bottle includes a stopper at its top, and further wherein the cap is configured to cover the stopper; piercing the stopper with an infusion line needle proximal to the infusion line; opening a movable hanger into an annular configuration from a label adhered to the bottle, wherein the movable hanger is part of the label and configured to move from a closed configuration to the annular configuration; and suspending the bottle on an infusion stand via the movable hanger.

[0010] In some variations, one or more features disclosed herein, including the following features, may optionally be included in any feasible combination. In some variations, the method may further include opening a vent cap on the infusion line needle; and setting an infusion rate and volume on the infusion pump for the drug to be administered to the patient, such that the drug travels from a bottle through the infusion line needle through the infusion line to a needle inserted into the patient, wherein the needle may be positioned at the distal end of the infusion line, and further wherein the infusion pump may be connected to the infusion line to pump the drug at the infusion rate. In some variations, the method may further include administering a second drug to the patient via the infusion pump and, upon completion of drug administration to the patient, through the infusion line, wherein the second drug may be a drug of the same or different type as the first drug. In some variations, the method may further include infusing a second volume of saline solution via the infusion pump into the infusion line. In some variations, after infusing a second volume of saline at an infusion rate of approximately 3 mL / min for approximately 30 minutes, less than 1.5% of the initial drug volume may remain in the infusion line, wherein the infusion time may include the drug administration time and the second saline flushing time. In some variations, after infusing a second volume of saline at an infusion rate of approximately 6 mL / min for approximately 10 minutes, less than 5% of the initial drug volume may remain in the infusion line, wherein the infusion time may include the drug administration time and the second saline flushing time. In some variations, the drug may be undiluted before administration. In some variations, the initial drug volume in the vial may be less than approximately 30 mL. In some variations, the movable hanger may be formed from a portion of the back surface area of ​​a label and the opposite portion of the front surface area. In some variations, the label may include perforations extending through both the back and front surface areas of the label, and the perforations may further define at least a portion of the periphery of the movable hanger. In some variations, the perforation can be configured to open the movable hanger from a closed configuration into a ring configuration.

[0011] In another related aspect, an apparatus is provided. The apparatus includes means for infusing a first volume of saline solution into an infusion line; means for infusing a drug from a bottle into the infusion line to administer the drug to a patient; and means for infusing a second volume of saline solution into the infusion line upon completion of drug administration to the patient. The bottle is suspended from an infusion stand via a movable hanger formed by a portion of a label adhered to the bottle, wherein the movable hanger causes movement from a closed configuration to an annular configuration.

[0012] In another related aspect, a method for administering a medication to a patient in need is provided. The method includes infusing a first volume of saline solution into the patient via an infusion line; infusing a predetermined volume of medication from a vial into the patient via the infusion line for a first time period, wherein the initial volume of the medication in the vial is less than or equal to about 30 mL and is undiluted prior to infusion into the patient; and infusing a second volume of saline solution into the patient via the infusion line for a second time period. After the second volume of saline solution is infused, less than about 5% of the initial volume of medication remains in the infusion line.

[0013] In some variations, one or more of the features disclosed herein, including the following characteristics, may optionally be included in any feasible combination. In some variations, the drug may be administered at a fixed dose. In some variations, the initial volume of drug in the vial may be less than or equal to about 10 mL. In some variations, the total duration of the first and second time periods may be less than or equal to about 60 minutes. In some variations, the total duration of the first and second time periods may be less than or equal to about 30 minutes. In some variations, the total duration of the first and second time periods may be less than or equal to about 15 minutes. In some variations, less than about 1.5% of the initial volume of drug may remain in the infusion line after the second volume of saline is infused. In some variations, the infused volume of drug may be between about 10 mL and about 30 mL, and the second volume of saline may be between about 25 mL and about 90 mL. In some variations, the drug and the second volume of saline may be infused into the patient at an infusion rate between about 1 mL / min and about 10 mL / min.

[0014] Details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Further features and advantages of the subject matter described herein will become apparent from the description, the accompanying drawings, and the claims. Attached Figure Description

[0015] The accompanying drawings, incorporated in and forming part of this specification, illustrate certain aspects of the subject matter disclosed herein and, together with the description, help explain some principles associated with the disclosed embodiments. In the drawings:

[0016] Figure 1A , Figure 1B , Figure 2A and Figure 2B Features of a movable hanger label consistent with an implementation of the present subject are shown, which is configured to adhere to and support the bottle;

[0017] Figure 3A and Figure 3B This illustrates various aspects of an adhesive, movable hanger label for bottles, consistent with the implementation of the present topic;

[0018] Figure 4 This is a schematic diagram showing various aspects of an infusion line needle for direct drug delivery, wherein a movable hanger label consistent with the implementation of the present subject matter may be used.

[0019] Figure 5A This is a graph of atezolizumab (atezo) concentration as a function of time, consistent with the implementation of the present subject, for an infusion of 840 mg dose of atezolizumab over 30 minutes at an infusion rate of 3 mL / min.

[0020] Figure 5B This is a graph of atezolizumab (atezo) concentration as a function of time, consistent with the implementation of the present topic, for an infusion of 840 mg dose of atezolizumab over 10 minutes at an infusion rate of 6 mL / min.

[0021] Figure 6A This is a graph of atezolizumab (atezo) concentration as a function of time, consistent with the implementation of the present topic, for a 1200 mg dose of atezolizumab infused over 30 minutes at an infusion rate of 3 mL / min.

[0022] Figure 6B This is a graph showing the concentration of atezolizumab (atezo) as a function of time, consistent with the implementation of the present topic, for an infusion of 1200 mg of atezolizumab over 10 minutes at an infusion rate of 6 mL / min.

[0023] Figure 7A This is a graph showing the concentration of atezolizumab (atezo) as a function of time, consistent with the implementation method of the present subject, for an infusion of 1680 mg of atezolizumab over 30 minutes at an infusion rate of 3 mL / min; and

[0024] Figure 7B This is a graph showing the concentration of atezolizumab (atezo) as a function of time, consistent with the implementation method of the present subject, for an infusion of 1680 mg of atezolizumab over 10 minutes at an infusion rate of 6 mL / min.

[0025] In practical applications, similar reference numerals indicate similar structures, features, or elements. Detailed Implementation

[0026] I. Definition

[0027] "Patient" or "subject in need" means a living organism that suffers from or is susceptible to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, cattle, rats, mice, dogs, cats, monkeys, goats, sheep, dairy cows, deer, and other non-mammalian animals. In some embodiments, the patient is a human.

[0028] Dosage may vary depending on the patient's needs and the compound used. In the context of this disclosure, the dose administered to the patient should be sufficient to achieve a beneficial therapeutic effect in the patient over time. The magnitude of the dose will also depend on the presence, nature, and extent of any adverse side effects. Determining the appropriate dose for a particular situation is within the skill level of a practitioner. Dosage and intervals can be individually adjusted to provide various levels of efficacy of the administered compound effective for the specific clinical indication being treated. This will provide a treatment regimen corresponding to the severity of the individual's disease state.

[0029] II. Pharmaceutical Composition

[0030] As used herein, "anticancer agent" refers to molecules (e.g., compounds, peptides, proteins, nucleic acids) used to treat cancer by destroying or inhibiting cancer cells or tissues. Anticancer agents may be selective for certain cancers or certain tissues. In the embodiments, the anticancer agents described herein may include epigenetic inhibitors and multi-kinase inhibitors.

[0031] "Anticancer drug" and "anticancer agent" are used in their usual, ordinary sense to refer to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) that has antitumor properties or the ability to inhibit cell growth or proliferation. In some embodiments, an anticancer agent is a chemotherapeutic agent. In some embodiments, an anticancer agent is a biological agent. In some embodiments, an anticancer agent is an immunotherapy agent. In some embodiments, an anticancer agent is an immune checkpoint inhibitor. In some embodiments, an anticancer agent is a pharmaceutical agent that is effective in methods of treating cancer as identified herein. In some embodiments, an anticancer agent is a pharmaceutical agent approved by the FDA or a similar regulatory agency in a country outside the United States for the treatment of cancer. Examples of anticancer agents include, but are not limited to: MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selmetinib / AZD6244, GSK1120212 / trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosourea, nitrogen mustard).Mustard (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethyleneimine and methylmelamine (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine) Streptozotocin), triazine (dacarbazine), antimetabolites (e.g., 5-thiozolidine, folate, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid-like substances (e.g., methotrexate) or pyrimidine analogs (e.g., fluorouracil, fluxouridine, cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinorelbine, vinorelbine, etc.). Antibiotics include: vinorelbine, podophyllotoxin, paclitaxel, docetaxel, topoisomerase inhibitors (e.g., irinotecan, topotecan, acridine, etoposide (Vp16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, doxorubicin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, procainoxine, etc.), platinum compounds (e.g., cisplatin, oxaloplatin, carboplatin), anthraquinones (e.g., mitoxantrone), and substituted ureas (e.g., hydroxyurea). Methylhydrazine derivatives (e.g., procarbazine), adrenocortical inhibitors (e.g., mitotane, aminoglutethimide), epipodophyllotoxin (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), mitogen-activated protein kinase signaling inhibitors (e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY).43-9006, Wortmannin or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituximab), gossyphol, genasense, polyphenol E, Chlorofusin, all-trans retinoic acid (ATRA), lichen styramine, tumor necrosis factor-associated apoptosis-inducing ligand (TRAIL), 5-aza-2′-deoxycytidine, all-trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldemycin, 17-propenylamino-17-demethoxygeldemycin (17-AAG), Flavoiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25-dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; arubibrine; acylfulvene; adenypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; aifostine; aminolevulinic acid; arubibrine; acridine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1 Protein-1; anti-androgens, prostate cancer; anti-estrogens; anti-tumor ketones (antineoplaston); antisense oligonucleotides; aphidicolinglycinate; apoptosis gene modulator; apoptosis regulator; apurinic nucleic acid; ara-CDP-DL-PTBA; arginine deaminase; asularine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin3; azasetron; azatoxin; azatyrosine; berry gibberellin III derivative; balanol; batimastat; BCR / ABL antagonist; benzochlorins; benzoylstaurosporine; β-lactam derivative; beta-alethine; beta-clarithromycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; brompirimine; budotitane; sulfoxide of butylthionine; calcipotriol; calphostin C; Camptothecin derivatives; Canarypox IL-2; Capecitabine; Formamide-amino-triazole; Carboxyamine-triazole; CaRest M3; CARN 700; Chondroitin-derived inhibitors; Carzelesin; Casein kinase inhibitors (ICOS); Spermine; Cecropin B; Cetrorelix; Dihydroporphyrin; Chloroquinoxaline sulfonamide; Cicaprost; Cisporphyrin; Cladribine; Clomiphene analogs; Clotrimazole; Collosimycin A; Collosimycin B; Combretastatin A4; Combretastatin analogs; Conagenin; Crambescidin 816; Crisnatol; Nostocin 8; Nostocin A derivatives; Curacin A A); Cyclopentanthraquinones; Cycloplatam; Cypemycin; Cytarabine phospholipids; Cytolysin; Intracellular inhibitor; Dacizumab; Decitabine; Dehydrodidemnin B; Diloxacin; Dexamethasone; Dextromethorphan; Dextromethorphan; Dextromethorphan; Dextromethorphan; Diaziquone; Dextromethorphan B; Didox; Diethylnorspermine; Dihydro-5-azacytidine; 9-dioxomycin; Diphenylspiromostatin; Docosanol; Doxorasetron; Deoxyfluorouridine; Droloxifene; Drolactam; Duocarmycin SASA); Ebuselenium; Ekomustine; Edifosine; Ezocurumab; Elonisene; Elimite; Ethiribut; Epirubicin; Eprepitant; Estrogen-mustine analogs; Estrogen agonists; Estrogen antagonists; Ethidazole; Etoposide phosphate; Exemestane; Fazodazole; Fazalabin; Fenretinide; Filgrass; Finasteride; Flavopiridol; Flucallastine; Fluasterone; Fludarabine; Fludaunorunicin hydrochloride; Folicanimex; Formexestane; Forstriol; Formosine; Gadolinium Tetraphyrin; Gallium nitrate; Galotetabine; Ganirelix; Gelatinase inhibitor; Gemcitabine; Glutathione inhibitor; Hepsulfam; Heregulin; Hexamethylene diacetamide; Hypericin; Ibandronic acid; Idarubicin; Edocefen; Icaramone; Emofocin; Ilomasta; Imidazolone; Imiquimod; Immunostimulatory peptide; Insulin-like growth factor-1 receptor inhibitor; Interferon agonist; Interferon; Interleukin; Iodobenzylguanidine; Iodoxorubicin; 4-Sweet potato picrol; Iloprapane; Isopridine; Isohomohalicondrin B; Itasetron; Jasplakinolide; Kahalalide F; lamellarin-Ntriacetate; lanreotide; leinamycin; levofloxacin; lentinan sulfate; leptolstatin; letrozole; leukemia inhibitory factor; leukocyte alpha interferon; leuprorelin + estrogen + progesterone; leuprorelin; levamisole; liazol; linear polyamine analog; lipophilic disaccharide peptide; lipophilic platinum compound; lissoclinamide 7; lomolybdenum; earthworm phospholipids; lometroxone; chlordamine; loxoanthraquinone; lovastatin; loxoribin; letopecan; lutetium texaphyrin; lysofylline; cleavage peptide; mannostatin A; Malimastastat; Masoronol; Mammary serine; Matrix dissolving factor inhibitor; Matrix metalloproteinase inhibitor; Minoliqui; Merbarone; Meterelin; Methionase; Metoclopramide; MIF inhibitor; Mifepristone; Mitefoxin; Milistatin; Mismatched double-stranded RNA; Mitoguanidine hydrazone; Mitogenic lactam; Mitomycin analogue; Mitonaphthylamine; Mitotoxin fibroblast growth factor-saponinFactor-saporin; Mitoxantrone; Mofarotin; Molgramostim; Monoclonal antibody; Human chorionic gonadotropin; Monophosphoryl lipid A+ myobacterium cell wall SK; Mopiperol; Multidrug resistance gene inhibitors; Therapeutic agents based on multiple tumor suppressor factor 1; Mustard anticancer agents; Mycaperoxide B; Mycobacterium cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamide; nafarilin; nagrestip; naloxone + pentazocine; napavin; napterpin; natosine; nedaplatin; nemorubicin; neridonic acid; neutral endopeptidase; nilumethicone; nisamycin; nitric oxide regulator; nitrogen oxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotide; ondansetron; ondansetron; oracin; oral cytokine inducer; omaliplatin Oxalidone; Oxaliplatin; Oxaunomycin; Palauamine; Palmitoylrhizoxin; Pamidronic acid; Ginsenoside Triol; Panomiphen; Parabactin; Pazelliptine; Pegaspargase; Peldesine; Sodium Pentosan Polysulfate; Pentostatin; Pentrozole; Perfluorobromoethane; Perphosphamide; Perperylene; Phenazinomycin; Phenyl acetate; Phosphatase inhibitors; Streptomycin preparations; Pilocarpine hydrochloride; Pirarubicin; Pyrithioxine; Placental A A); Placetin B; Plasminogen activator inhibitor; Platinum complex; Platinum compound; Platinum-triamine complex; Porphyrin sodium; Pofibromycin; Prednisone; Propylbis-acridone; Prostaglandin J2; Proteasome inhibitor; Protein A-based immunomodulators; Protein kinase C inhibitor; Protein kinase C inhibitor; Microalgae; Protein tyrosine phosphatase inhibitor; Purine nucleoside phosphorylase inhibitor; Red pigment; Pyrazoloacridine; Pyridine-oxygenated hemoglobin polyoxyethylene conjugate; RAF antagonist; Raltitrexate; Ramosetron; RAS farnesyltransferase inhibitor; RAS inhibitor; RAS-GAP inhibitor; Demethylated retepritin; Re 186 etidronate; Rhizomycin; Ribozyme; RII retinamide; Rogulimine; Roxithromycin; Romotide; Roquimec; RubiginoneB1; Paclitaxel; Safingo; Saintopin; SarCNU; Sarcophytol A; Saxaglastine; Sdi 1 mimic; Semustine; Senescence-derived inhibitor 1; Significant oligonucleotide; Signal transduction inhibitor; Signal transduction modulator; Single-chain antigen-binding protein; Sizofuran; Sobuzosen; Borcarb sodium; Sodium phenylacetate; Solvent; Somatostatin-binding protein; Sonermin; Sparfosic acid; Spicamycin D; Spiromustine; Splenopentin; Spongistatin 1 1); Squalamine; Stem cell inhibitor; Stem cell division inhibitor; Stipiamide; Lysolysin inhibitor; Sulfinosine; Potent vasoactive intestinal peptide antagonist; Suradista; Suramin; Sorghum extract; Synthetic glycosaminoglycans; Tamustine; Tamoxifen; Tazarotene; Tecogallan sodium; Tegafur; Tellurapyrylium; Telomerase inhibitor; Temoporphyrin; Temozolomide; Teniposide; Tetrachlorodecaoxide; Tetrazodamine; Thaliblastine; Thiocoraline; Thrombopoietin; Thrombopoietin mimics; Thymofasin; Thymopoietin receptor agonist; Thymotrene; Thyroid-stimulating hormone; Tin ethyl pyrrolidone etiopurpurin); tirazamine; titanocetamide; topsentin; toremifene; pluripotent stem cell factor; translation inhibitor; retinoic acid; triacetyluridine; tricerebroside; trimethoprim; triptorelin; tropisetron; tolostaniel; tyrosine kinase inhibitor; tyrosine phosphorylation inhibitor; UBC inhibitor; ubenimex; urogenital sinus-derived growth inhibitor; urokinase receptor antagonist; vaporpeptide; variolin B; Vector systems, erythrocyte gene therapy agents; Veraratezol; Veratrilamide; Verdins; Vertepofen; Vinorelbine; Vinxaltine; Vitaxin; Vocinolone; Zanoteron; Zyraxol; Zilascorb; Nettostatin; Doxorubicin; Dermazomycin; Vincristine; Cisplatin; Acivitin; Arubicin; Adalazine; Aldehyde Interleukin; Hexamethylmelamine; Dimycin; Ametantrone acetate; Aminoglutamine; Acridil; Anastrozole; Aminoglutamine; Asparaginase; Triamcinolone; Azacitidine; Azatiprine; Nitrosaccharin; Bamasta; Bentepep; Bicalutamide; BisnafideDimesylate; Bleomycin sulfate; Bleomycin sodium; Brompirimidine; Busulfan; Actinomycin; Capprotestone; Carbetamide; Carbetin; Carboplatin; Carmustine; Carminoxetine hydrochloride; Carzelosin; Sildenafil; Chlorpyrifos; Clindrone; Clinapordine mesylate; Cyclophosphamide; Vidaracin; Dacarbazine; Daunorubicin hydrochloride; Decitabine; Dextromethorphan; Dezaguanine; Dezaguanine mesylate; Ascorbicone; Doxorubicin hydrochloride; Droloxifene; Droloxifene citrate; Drolbutazone propionate; Dazomycin; Edatraxa; Eflunomide hydrochloride; E Salrucin; Enloplatin; Enpromethazine; Epiloperidol; Epirubicin Hydrochloride; Ibuproazole; Exorubicin Hydrochloride; Estrostustin; Estrostustin Sodium Phosphate; Ethanidazole; Etoposide; Etoposide Phosphate; Etobuline; Faldrozol Hydrochloride; Fazalabin; Retinoylphenol; Fluorouracil; Fludarabine Phosphate; Fluorouracil; Fluciacidine; Fluciacidine; Phosphorione; Forstrocin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Imofosine; Interleukin I1 (including recombinant interleukin II or RL1L). sub.2); Interferon α-2a; Interferon α-2b; Interferon α-n1; Interferon α-n3; Interferon β-1a; Interferon γ-1b; Isopropylplatin; Irinotecan hydrochloride; Lanreotide acetate; Letrozole; Leuprorelin acetate; Riazol hydrochloride; Lometroxodium sodium; Lomustine; Loxoanthraquinone hydrochloride; Masrophenone; Maytansine; Dichloromethyldiethylamine hydrochloride; Medroxyprogesterone acetate; Melenoprogesterone acetate; Mefenoxuron; Minoril; Mercaptopurine; Methotrexate; Methotrexate sodium; Chlorpheniramine; Metotepamine; Mildolidomide; Mitocarcin; Mitocarcin; Mitocarcin; Mitocarcin Mitomycin; Mitomycin; Mitomycin; Mitomycin; Mitoxantrone hydrochloride; Mycophenolic acid; NocodazoIe; Nogamycin; Omaplatin; Oxysulphuron; Pegaspargase; Perymycin; Pendimethalin; Pelosimethicone sulfate; Pephosphatamide; Piperabromide; Piperabromide; Roantrone hydrochloride; Procainamide; Promethene; Porphyrin sodium; Methylmitromycin; Prenimustine; Procarbazine hydrochloride; Puromycin; Puromycin hydrochloride; Pyrazofuranin; Lipoadenosine; Rogulam; Safungo; Safungo; Semustine; Citric acid; Sparfosate sodiumSodium); Sparmycin; Spiramostegium hydrochloride; Spiramostegium; Spiramostegium; Streptozotocin; Streptozotocin; Sulfonamide; Talimycin; Tecogallan sodium; Tegafur; Teloanthraquinone hydrochloride; Temoporphen; Teniposide; Tiroxicoron; Testrolide; Thiomipurin; Thioguanine; Thiotepa; Thiazole carboxylamine nucleoside; Tilazamin; Toremifen citrate; Tritolon acetate; Tricyclobutanil phosphate; Trimethotraxa; Trimethotraxa glucuronide; Triptorelin; Tobradazole hydrochloride; Uramustine; Uretipa; Vapotetide; Vertepofen; Vincristine sulfate; Vincristine sulfate Alkali; vinorelbine; vinorelbine sulfate; vinpidin sulfate; vinblastine sulfate; vinrocin sulfate; vinorelbine tartrate; vinrocin sulfate; vinorelbine sulfate; vorticazole; zeniplatin; netsistatin; zorubicin hydrochloride; agents that arrest cells in the G2-M phase and / or regulate microtubule formation or stability (e.g., Taxol™ (paclitaxel), Taxotere™, compounds containing a taxane skeleton), irbuproazole (R-55104), dolastatin 10 10) (i.e., DLS-10 and NSC-376128), Mivobulinisethionate (i.e., CI-980), Vincristine, NSC-639829, Discodermolide (i.e., NVP-XX-A-296), ABT-751 (Abbott, i.e., E-7010), Altorhyrtins (e.g., Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g., Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8 and Spongistatin 9), Cemadotin hydrochloride Hydrochloride (i.e., LU-103793 and NSC-D-669356), Epothilones (e.g., Epothilone A, Epothilone B, Epothilone C (i.e., deoxyepothilone A, or dEpoA), Epothilone D (i.e., KOS-862, dEpoB, and deoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B)B), 21-aminoepothilone B (i.e., BMS-310705), 21-hydroxyepothilone D (i.e., desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e., NSC-654663), Soblidotin (i.e., TZT-1027), LS-4559-P (Pharmacia, i.e., LS-4577), LS-4578 (Pharmacia, i.e., LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e., WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences) Sciences), BSF-223651 (BASF, i.e., ILX-651 and LU-223651), SAH-49960 (Lilly / Novartis), SDZ-268970 (Lilly / Novartis), AM-97 (Armad / Kyowa Hakko), AM-132 (Armad), AM-138 (Armad / KyowaHakko), IDN-5005 (Indena), Cryptophycin 52 (i.e., LY-355703), AC-7739 (Ajinomoto, i.e., AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, i.e., AVE-8062, AVE-8062A, CS-39-L-Ser.HCl and RPR-258062A), Vitilevuamide, Tubulysin A. Canadensol, Centaureidin (NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067, and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), OncocidinA1 (i.e., BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e., SPIKET-P), 3-IAABU (Cytoskeleton / Mt. Sinai School of Medicine, i.e., MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton / Mt. Sinai School of Medicine, i.e., MF-191), TMPN (Arizona State University), Vanadocene (acetylacetone dicyclopentadiene vanadium). acetylacetonate), T-138026 (Tularik), Monsatrol, innanocine (i.e., NSC-698666), 3-IAABE (Cytoskeleton / Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e., T-900607), RPR-115781 (Aventis), eleutherobin (such as desmethyleleutherobin, desaetyleleutherobin, isoeleutherobin A and Z-eleutherobin)), Caribaeolin, soft sponge B, D-64131 (Asta Medica), D-68144 (AstaMedica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (NSCL-96F037), D-68838 (AstaMedica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e., D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e., SPA-110, trifluoroacetate) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin sodium phosphate, BPR-OY-007 (National Health Research...Institutes and SSR-250411 (Sanofi)), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprorelin, adrenocorticotropic hormones (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinylestradiol), anti-estrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate, flumethasone), anti-androgens (e.g., flutamide), immunostimulants (e.g., BCG, levamisole, interleukin-2, interferon-alpha, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-galactasmycin conjugate, anti-C D22 monoclonal antibody-Pseudomonas aeruginosa exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to 111In, 90Y, or 131I, etc.), triptolide, homoharringtonine, actinomycin D, doxorubicin, epirubicin, topotecan, itraconazole, vinblastine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR) targeted therapies or agents (e.g., gefitinib). TM ), erlotinib (Tarceva) TM ), cetuximab (Erbitux) TM Lapatinib (Tykerb) TM Panitumumab (Vectibix) TM ), Caprelsa TM(Afatinib / BIBW2992, CI-1033 / cannatinib, neratinib / HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib / PF299804, OSI-420 / desmethyl erlotinib, AZD8931, AEE788, pelitinib / EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, etc. In one embodiment, the anticancer agent is an immune checkpoint inhibitor (e.g., atezolizumab). pembrolizumab Ipilimumab and nivolumab Avelumab, Durvalumab, Cemiplimab, or Spartalizumab.

[0032] III. How to Use

[0033] As used herein, unless otherwise stated, the term "administration" generally refers to intravenous administration. Other routes of administration include, but are not limited to: suppository, topical contact, oral, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, subcutaneous administration, implantation of sustained-release devices (e.g., microosmotic pumps), and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or percutaneous) administration. Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intravenous, and intracranial administration. Other drug delivery methods include, but are not limited to, the use of liposomal formulations and transdermal patches.

[0034] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and various modifications or changes thereof will be suggested to those skilled in the art and will be included within the spirit and scope of this application and the appended claims.

[0035] IV. Explanation

[0036] The present subject matter relates to the direct infusion of medications from a bottle to a patient. Consistent with the implementation of the present subject matter, a movable hanger tag is provided to adhere to and support the bottle to facilitate the direct infusion of medications, such as one or more pharmaceuticals, biotechnological drugs, and / or biologics, from the bottle to a patient.

[0037] For routine drug infusion procedures, one or more healthcare professionals may be responsible for administering medication intravenously. This may include, for example, a dosing preparation procedure and a patient preparation procedure to administer the medication directly to the patient via intravenous infusion. For instance, a dosing preparation procedure may involve one or more healthcare professionals preparing a diluted medication in an intravenous infusion bag, which consumes valuable time (e.g., the time spent by the healthcare professional preparing the diluted medication) and materials (e.g., the intravenous infusion bag). Furthermore, the dosing preparation procedure needs to be performed in a sterile environment, further consuming resources, including sterile equipment (e.g., healthcare professional gloves and masks) and hospital or clinic space. Additionally, because the preparation of diluted medication relies on interpersonal interaction, such dosing preparation procedures are inherently prone to error.

[0038] For patient considerations, routine drug infusion procedures typically require a significant amount of time to administer medication. When medications are diluted with, for example, normal saline, the volume of fluid delivered to the patient increases, thus increasing the time required for drug administration.

[0039] The movable pendant tag, consistent with the implementation methods described in this paper, simplifies conventional drug delivery procedures by providing a method for direct infusion of medication from the bottle to the patient. This reduces the time, materials, and space resources required in conventional dose preparation procedures. Furthermore, using the movable pendant tag for direct drug delivery to the patient reduces the time spent administering medication, thereby improving the overall patient experience.

[0040] Figures 1A to 2B Features of a movable hanger label 100 consistent with an implementation of the present subject are shown, which is configured to adhere to and support the bottle. Figure 1A This is a perspective view of the movable hanging label 100 when it is oriented in a planar orientation, and Figure 1B This is the front view of the movable hanging label 100 when it is in planar orientation. Figure 2A This is a perspective view of the movable hanger label 100 in a bent orientation (e.g., in a configuration where the movable hanger label 100 is attached to a bottle), and Figure 2B This is a perspective view of the movable hanger label 100 in a bent orientation, wherein the movable hanger portion 150 is in an open or ring-shaped configuration.

[0041] like Figures 1A to 2BAs shown, the movable hanger label 100 has a back surface region 102 and a front surface region 104 opposite to the back surface region 102. The back surface region 102 and the front surface region 104 are generally planar. A movable hanger portion 150 is formed by a portion of the back surface region 102 and the opposite portion of the front surface region 104 of the movable hanger label 100, and is configured to move from a first position (e.g., a closed position or closed configuration) to a second position (e.g., an open position or open configuration, or an annular position or annular configuration). In the first position (e.g., the closed position), the movable hanger portion 150 is aligned with the remaining area of ​​the movable hanger label 100. In the second position (e.g., the open position or annular position), the movable hanger portion 150 of the movable hanger label 100 is at least partially separated from the remaining area of ​​the movable hanger label 100. In other words, consistent with the implementation method of the present subject, the movable hanger portion 150 is part of the movable hanger label 100 and is movable relative to the movable hanger label 100 to form a ring or hanger 150 (e.g., Figure 2B (As shown).

[0042] Consistent with the implementation of the present subject matter, the movable hanger label 100 is perforated such that the movable hanger portion 150 is formed by a portion of the back surface region 102 of the movable hanger label 100 and the opposite portion of the front surface region 104. The perforation 152 allows the movable hanger portion 150 to be at least partially separated from the remainder of the movable hanger label 100, such that the movable hanger portion 150 is movable relative to the movable hanger label 100 (along the perforation 152), as... Figure 2B As shown. The perforation 152 defines at least a portion of the periphery of the movable hanging bracket portion 150, as... Figure 2B As shown. The movable hanger portion 150 can be peeled off from the rest of the movable hanger label 100 by clamping the first and / or second extended tabs or corner or end regions of the movable hanger portion 150 and peeling it off along the perforation 152.

[0043] The movable hanger portion 150 is secured to the movable hanger label 100 at the fixed end 154. The perforation 152 adjacent to or near the fixed end 154 may be in a curved form or the like to provide or facilitate movement (e.g., rotational movement) of the movable hanger portion 150. The curved form of the end region of the perforation 152 also prevents the movable hanger label 100 from tearing at the end region. For example, the movable hanger portion 150 can rotate approximately 180° from a closed position to an open position or an annular position, and the curved form of the end region of the perforation 152 provides rotational movement without tearing or minimal tearing of the movable hanger label 100 from the perforation 152.

[0044] Consistent with the embodiments described in the present subject matter, the movable hanger label 100 is made of a flexible material, allowing it to conform to the shape of the surface on which it is affixed. For example, the movable hanger label 100 can be made of flexible plastic or reinforced paper products. The movable hanger label 100 can adhere to bottles with curved outer walls, and can substantially conform to the curvature of the outer walls of the bottle. The movable hanger label 100 can conform to various surface shapes and is not limited to adhesion to and use with cylindrical bottles, but can also be used with, for example, cubic bottles.

[0045] The back surface area 102 of the movable hanger label 100 may include an adhesive material or substance that is pasted or adhered to various materials, such as glass, plastic, metal, etc. Consistent with embodiments of the present subject, a portion of the back surface area 102 forming the movable hanger portion 150 does not contain an adhesive material or substance, thereby allowing the movable hanger portion 150 to separate from the remainder of the movable hanger label 100 to move between a first position (e.g., a closed position) and a second position (e.g., an open or looped position) when the movable hanger label 100 is adhered to a bottle.

[0046] refer to Figures 3A to 3B This illustrates various aspects of the movable hanger label 100, consistent with the implementation of the present subject, when adhered to the bottle 300. Figure 3A The left side shows a movable hanger label 100 attached to bottle 300, with the movable hanger portion 150 in a closed configuration (or position). Figure 3A On the right side, the movable hanger portion 150 moves from the closed configuration (or position) to the open configuration (or position), wherein a type of hanger is formed by the separation and movement (e.g., rotational movement) of the movable hanger portion 150 away from the rest of the movable hanger label 100. As shown, the movable hanger portion 150 may take the form of a ring such that when the bottle 300 is inverted, the ring (located at the bottom of the bottle 300) faces upward, thereby allowing the bottle 300 to be attached or secured to the device, wherein the upper side of the bottle 300 is accessible. Figure 3BAs shown, this configuration provides the ability to administer the medication contained in the bottle 300 directly from the bottle 300 when the bottle is attached to or secured to (e.g., suspended) a device. For example, when the movable bracket portion 150 is in the open configuration, the bottle 300 can be secured to an infusion stand or the like by making the movable bracket portion 150 looped or otherwise secured to an arm or extension of an infusion stand. In this configuration, where the bottle 300 is supported by the movable bracket portion 150 of the movable bracket label 100 and the bottle 300 is oriented substantially downwards, the text and / or markings on the movable bracket label 100 can be upside down, face up, or a combination thereof. For example, consistent with the embodiments of the present subject, when the bottle 300 is in the upright position, the text and / or markings on the movable bracket label 100 can be upside down, thereby allowing the text and / or markings to face up when the bottle 300 is suspended and supported by the movable bracket portion 150.

[0047] Further reference Figure 3B The process 350 for preparing a bottle 300 with a movable hanger label 100 for drug administration to a patient containing a drug in the bottle 300 is shown.

[0048] At 355, the cap is removed from the bottle 300 containing the medication. As shown, a movable hanger tag 100 is attached to the bottle 300. In some examples, the bottle 300 may include a stopper at its top, and the cap may be configured to cover the stopper.

[0049] At 360°, the bottle stopper was punctured by the infusion line needle, which is connected to the infusion line. Figure 3B (Not shown in the image). In some examples, the infusion line needle pierces the center or near-center portion of the stopper. In some examples, the longitudinal orientation of the infusion line needle is 90° relative to the top surface of the stopper. In some examples, the longitudinal orientation of the infusion line needle is approximately 80°, approximately 81°, approximately 82°, approximately 83°, approximately 84°, approximately 85°, approximately 86°, approximately 87°, approximately 88°, approximately 89°, approximately 90°, approximately 91°, approximately 92°, approximately 93°, approximately 94°, approximately 95°, approximately 96°, approximately 97°, approximately 98°, approximately 99°, or approximately 100° relative to the top surface of the stopper.

[0050] At 365, the infusion line needle is inserted into bottle 300 through the stopper until a point is reached where at least the tip region of the infusion line needle is visible through bottle 300. For example, the infusion line needle is inserted into bottle 300 through the stopper until the infusion line needle is visible at the neck of bottle 300.

[0051] At 370, the process begins by moving the movable hanger portion 150 of the movable hanger label 100 from a first position (e.g., a closed position or closed configuration) to a second position (e.g., an open position or open configuration, or a loop position or loop configuration). In some examples, the first and / or second extended tabs or corner or end regions of the movable hanger portion 150 may be lifted or peeled off from the bottle 300 and the rest of the movable hanger label 100.

[0052] At 375, the process continues to move the movable hanger portion 150 of the movable hanger label 100 from the first position to the second position. Consistent with the embodiments of the present subject, the movable hanger portion 150 is torn and / or peeled off from the movable hanger label 100 along the perforation 152, as referenced above. Figures 1A to 2B As stated above.

[0053] At 380, when the movable bracket portion 150 is fully or nearly fully in the second position, forming a ring structure and capable of being clamped, the bottle 300 is inverted, while the infusion line needle is held in the proper position within the bottle. At 385, the bottle 300 is attached to a device such as an infusion rack or infusion rod via the movable bracket portion 150. Specifically, when the movable bracket portion 150 is in the open configuration, the bottle 300 can be secured to the infusion rack, infusion rod, etc., by making the movable bracket portion 150 ring-shaped or otherwise fixed to the arm or extension of the infusion rack or infusion rod. In this configuration, the bottle 300 is supported by the movable bracket portion 150 of the movable bracket label 100, and the bottle 300 is oriented substantially downwards.

[0054] Consistent with the implementation of the present subject matter, the movable bracket portion 150 can support a bottle 300 weighing up to approximately 500 kg. The movable bracket portion 150 can support a bottle 300 weighing up to approximately 50 kg, approximately 100 kg, approximately 150 kg, approximately 200 kg, approximately 250 kg, approximately 300 kg, approximately 350 kg, approximately 400 kg, or approximately 450 kg. The movable bracket portion 150 can support a bottle 300 weighing up to approximately 10 kg, approximately 15 kg, approximately 20 kg, approximately 25 kg, approximately 30 kg, approximately 35 kg, approximately 40 kg, or approximately 45 kg. The movable bracket portion 150 can support a bottle 300 weighing up to approximately 1 kg, approximately 2 kg, approximately 3 kg, approximately 4 kg, approximately 5 kg, approximately 6 kg, approximately 7 kg, approximately 8 kg, or approximately 9 kg. The movable hanging section 150 can support a weight of bottle 300 between approximately 0.5 kg and approximately 500 kg. The weight of the bottle can be any value or sub-range within the stated range, including the endpoints.

[0055] In some embodiments, the movable hanger portion 150 may be reinforced with additional support material to resist breakage and provide enhanced support for the bottle 300. In some embodiments, the movable hanger portion 150 may be made of a more robust material than the rest of the movable hanger label 100.

[0056] The movable hanger label 100 and the movable hanger portion 150 can have various sizes and shapes, and are not limited to specific sizes and shapes. For example, the total length of the movable hanger label 100 can be between approximately 75 mm and 100 mm, and the total height of the movable hanger label 100 can be between approximately 30 mm and 40 mm. The width of the support portion of the movable hanger section 150 (e.g., the portion where the bottle 300 is suspended when mounted or attached to a device) may be between about 5.0 mm and about 7.0 mm; for example, about 5.0 mm, about 5.1 mm, about 5.2 mm, about 5.3 mm, about 5.4 mm, about 5.5 mm, about 5.6 mm, about 5.7 mm, about 5.8 mm, about 5.9 mm, about 6.0 mm, about 6.1 mm, about 6.2 mm, about 6.3 mm, about 6.4 mm, about 6.5 mm, about 6.6 mm, about 6.7 mm, about 6.8 mm, about 6.9 mm, or about 7.0 mm. The thickness of the hanger label may be between about 0.05 mm and about 0.25 mm; for example, between about 0.15 mm and about 0.18 mm. Any indicated parameter may be any value or subrange within the stated range, including endpoints.

[0057] The movable hanger label 100 and the movable hanger portion 150 are not limited to the exemplary illustration. Figures 1A to 3B The dimensions, shapes, and proportions shown are not specified. Rather, the movable hanger label 100 and movable hanger portion 150, consistent with the embodiments of the present subject, can take the form of various sizes, shapes, and proportions. For example, the size and shape of the movable hanger label 100 and movable hanger portion 150 can be configured to accommodate various bottles or containers.

[0058] As described herein, the movable hanger tag 100 can be used to facilitate the direct infusion of the medication contained in the bottle into a patient. Consistent with the embodiments of the present subject matter, the medication contained in the bottle is undiluted prior to administration. The process for administering the medication contained in the bottle to a patient may include administering the medication to the patient using an infusion line and infusion pump, followed by infusing a saline flushing solution using the infusion line and infusion pump. The infusion line needle may be positioned proximally to the infusion line.

[0059] Figure 4 This is a schematic diagram illustrating various aspects of an example infusion line needle 410 for direct drug infusion, which can be adopted in accordance with embodiments of the present subject matter. Figure 4As shown, the infusion line needle 410 includes a drug port 412, a vent cap 414, and a body 416 in liquid communication with the drug port 412. The body 416 is connected to the infusion line 420, such that there is fluid communication from the drug port 412 through the body 416 to the infusion line 420. Figure 4 As shown, the infusion line needle 410 is configured to introduce a drug contained in the vial 300 into the infusion line 420. Other mechanisms may be used instead of the infusion line needle configuration. The infusion line 420 is connected to an infusion pump (not shown), which operates to pump the liquid or material contained in the infusion line 420 at a predetermined rate. At the distal end of the infusion line 420 is a needle (not shown) that is inserted into the patient to deliver the drug from the infusion line 420 to the patient.

[0060] Consistent with the implementation of the present subject matter, the process of administering medication using the movable hanger tag 100 may include infusing a first volume of saline solution into the infusion line. For example, the first volume of saline solution may be provided in a saline bag or container (containing, for example, 0.9% NaCl), and an infusion line needle (or other mechanism) may be connected to the saline bag or container to introduce (operated by an infusion pump) the first volume of saline solution. This may be done to remove air from the infusion line before the medication is infused into the patient (and before the needle is inserted into the patient).

[0061] The process can continue by removing the cap from the bottle containing the medication. In some examples, the bottle may include a stopper at its top, and the cap may be configured to cover the stopper. The stopper may be rubber or another elastic, compressible material to allow an infusion line needle to pierce the stopper, inserting the needle into the bottle and thus guiding the medication contained in the bottle to the infusion line.

[0062] The movable hanger tag 100 attached to the bottle can then be opened to move the movable hanger portion 150 from a first position (e.g., closed configuration) to a second position (e.g., open or ring-shaped configuration). As described herein, by moving the movable hanger portion 150 to the open or ring-shaped configuration, the bottle can be attached to a device to facilitate direct drug infusion from the bottle. For example, the bottle can be suspended from an infusion stand, etc., via the movable hanger portion 150.

[0063] Once the bottle is correctly positioned, the vent cap on the infusion line needle can be opened, and the infusion pump's infusion rate and volume can be set to administer medication to the patient. When the infusion pump starts running at the predetermined infusion rate, the medication travels from the bottle through the infusion line needle, through the infusion line, and to the needle inserted into the patient's body at the distal end of the infusion line.

[0064] V. Application Method

[0065] In one aspect, a method for administering medication intravenously to a patient is provided. This method may utilize a bottle with a removable hanger tag as described herein, or any other bottle or container suitable for this purpose.

[0066] This method involves administering a drug to a patient intravenously, without diluting the drug prior to administration. In one embodiment, the method further includes administering normal saline intravenously to the patient after drug administration. Infusing this normal saline can "flush" the infusion line and reduce the amount of drug remaining in the line after administration. For small doses of drug (e.g., less than or equal to about 60 mL, or less than or equal to about 40 mL), this step can allow the patient to receive the full dose of drug. Compared to standard administration methods, this method also reduces the total time spent administering the drug to the patient (drug administration plus normal saline flushing).

[0067] This method may include infusing a first volume of saline (or other suitable liquid) into the infusion line. For example, the first volume of saline may be provided in a saline bag or container (containing, for example, 0.9% NaCl) and introduced into the infusion line (via pump operation). This may be done to remove air from the infusion line before the medication is infused into the patient (and before the needle is inserted into the patient).

[0068] Medications can be administered using an infusion pump. After the first dose of medication has been administered to the patient, a second medication can be administered following the same or similar procedure. The second medication may be the same type as or a different type from the first. After the first dose of medication has been administered or after the second medication has been administered, the infusion line can be flushed with a second volume of saline solution. For example, once a dose of medication has been dispensed, the infusion line can be transferred to a saline bag or container containing saline solution (e.g., 0.9% NaCl) to flush the infusion line.

[0069] Consistent with the implementation of the present subject matter, after infusing a second volume of saline at an infusion rate of approximately 3 mL / min for approximately 30 minutes, less than 1.5% of the initial drug volume remains in the infusion line. The infusion time may include the drug administration time and the time for the second saline flush.

[0070] Consistent with the implementation of the present subject matter, after infusing a second volume of saline at an infusion rate of approximately 6 mL / min for approximately 10 minutes, less than 5% of the initial drug volume remains in the infusion line. Similarly, the infusion time may include the drug administration time and the time for the second saline flush. The initial drug volume in the bottle may be less than approximately 30 mL.

[0071] Consistent with other embodiments of the present subject matter, a method for administering a drug to a patient may include: infusing a first volume of saline solution into the patient via an infusion line, and then infusing a predetermined volume of drug from a vial into the patient for a first time period via the infusion line. The drug may be administered at a fixed dose (e.g., the same dose regardless of the patient's age and / or weight).

[0072] The initial volume of the drug in the vial may be less than or equal to about 30 mL. In some embodiments, the drug is not diluted before infusion into the patient. In some embodiments, the initial volume of the drug in the vial is between about 1 mL and about 30 mL. In some embodiments, the initial volume of the drug in the vial is between about 1 mL and about 20 mL. In some embodiments, the initial volume of the drug in the vial is between about 1 mL and about 15 mL. In some embodiments, the initial volume of the drug in the vial is between about 5 mL and about 30 mL. In some embodiments, the initial volume of the drug in the vial is between about 10 mL and about 30 mL. In some embodiments, the initial volume of the drug in the vial is between about 15 mL and about 30 mL. In some embodiments, the initial volume of the drug in the vial is between about 5 mL and about 25 mL. In some embodiments, the initial volume of the drug in the vial is between about 5 mL and about 20 mL. In some embodiments, the initial volume of the drug in the vial is between about 5 mL and about 15 mL. This volume can be any value or subrange within the described range, including endpoints.

[0073] In some embodiments, the initial amount of medication in the bottle is less than or equal to about 30 mL, about 29 mL, about 28 mL, about 27 mL, about 26 mL, about 25 mL, about 24 mL, about 22 mL, or about 21 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 20 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 19 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 18 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 17 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 16 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 15 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 14 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 13 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 12 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 11 mL. In some cases, the initial amount of medication in the bottle is less than or equal to about 10 mL. In some embodiments, the initial amount of medication in the bottle is less than or equal to about 5 mL.

[0074] The second volume of saline solution can then be infused into the patient via the infusion line for a second time period. Consistent with the embodiments of the present subject, less than 10% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In some embodiments, less than 9%, 8%, 7%, or 6% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In some embodiments, less than 5% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In some embodiments, less than 4% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In some embodiments, less than 3% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In some embodiments, less than 2% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In other cases, less than 1.5% of the initial amount of the drug may remain in the infusion line after the second volume of saline solution is infused. In some embodiments, after the second volume of saline is infused, less than 1% of the initial amount of the drug may remain in the infusion line.

[0075] In some embodiments, after infusion of the second volume of saline, an amount between about 0% and 10% of the initial dose of the drug may remain in the infusion line. In some embodiments, after infusion of the second volume of saline, an amount between about 0% and 5% of the initial dose of the drug may remain in the infusion line. In some embodiments, after infusion of the second volume of saline, an amount between about 0% and 1.5% of the initial dose of the drug may remain in the infusion line. In some embodiments, after infusion of the second volume of saline, an amount between about 1% and 5% of the initial dose of the drug may remain in the infusion line. In some embodiments, after infusion of the second volume of saline, an amount between about 1.5% and 5% of the initial dose of the drug may remain in the infusion line. This amount can be any value or subrange within the stated range, including endpoints.

[0076] The sum of the first time period (time for drug infusion) and the second time period (time for saline flushing) can be less than or equal to about 60 minutes, less than or equal to about 30 minutes, or less than or equal to about 15 minutes.

[0077] In one embodiment, the sum can be between about 5 minutes and about 60 minutes. In another embodiment, the sum can be between about 5 minutes and about 45 minutes. In another embodiment, the sum can be between about 10 minutes and about 45 minutes. In another embodiment, the sum can be between about 10 minutes and about 30 minutes. In another embodiment, the sum can be between about 15 minutes and about 30 minutes. In another embodiment, the sum can be between about 5 minutes and about 25 minutes. In another embodiment, the sum can be between about 5 minutes and about 20 minutes. The time amount can be any value or subrange within the stated range, including endpoints.

[0078] The infusion volume of the drug can be between approximately 10 mL and approximately 30 mL, and the second volume of normal saline can be between approximately 25 mL and approximately 90 mL.

[0079] In some embodiments, the second volume of saline solution may be between about 20 mL and about 100 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 90 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 80 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 70 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 60 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 50 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 40 mL. In some embodiments, the second volume of saline solution may be between about 25 mL and about 30 mL. This volume may be any value or subrange within the described range, including endpoints.

[0080] The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate between about 1 mL / min and about 10 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate between about 2 mL / min and about 10 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate between about 3 mL / min and about 10 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate between about 1 mL / min and about 8 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate between about 1 mL / min and about 6 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate of about 1 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate of about 2 mL / min. The medication and / or a second volume of saline solution may be infused into the patient at an infusion rate of about 3 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 4 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 5 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 6 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 7 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 8 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 9 mL / min. The medication and / or a second volume of saline may be infused into the patient at an infusion rate of approximately 10 mL / min. This volume can be any value or subrange within the stated range, including endpoints.

[0081] Example

[0082] Example 1: Rapid and Immediate Infusion (RRTI) of Atezolizumab

[0083] By allowing direct infusion (The cancer immunotherapy drug atezolizumab) and enabling rapid infusion (e.g., intravenous infusion over 10 minutes) to simplify dosage preparation can improve the experience for healthcare professionals and patients.

[0084] The RRTI (Responsive Infusion Protocol) method for intravenous infusion allows medication to be administered directly from the primary packaging (e.g., vial), which can streamline the workflow for healthcare professionals. Rapid medication infusion (e.g., a 10-minute infusion time) can further improve the patient experience. Therefore, It is a good candidate for RRTI because it is a liquid formulation (no need to reformulate) and is provided in a fixed dose.

[0085] The following is an example procedure for the rapid infusion of liquid medications (e.g., atezolizumab) from a vial. First, permeate the infusion line with physiological saline (e.g., 0.9% NaCl) before insertion. Remove the vial cap and puncture the center of the rubber stopper with an infusion needle. Figure 4 The separate infusion line needle (top) and the infusion line needle (bottom) after insertion of the vial are shown. Ensure the drug port portion is positioned at the neck of the vial, close to the stopper, as shown. Figure 4 Open the hanger label as shown at the bottom, then hang the bottle upside down on the IV stand. Open the vent cap on the infusion line and set the infusion rate and infusion volume (VTBI) according to Table 1, and begin the infusion. For example, for a 1680 mg dose, set the VTBI to 14.0 mL and begin the infusion. After the infusion is complete, open another 15 cc bottle and repeat this protocol. Set the VTBI to 14.0 mL and begin the infusion. After dispensing the required dose, transfer the infusion line to a container filled with 0.9% NaCl to flush the line, and set the infusion rate and VTBI according to Table 1.

[0086] Depending on the indication and the regimen to be used, atezolizumab can be administered in three different doses (840 mg, 1200 mg, and 1680 mg). Currently, atezolizumab is diluted in a 250 mL infusion bag containing 0.9% sodium chloride injection USP before administration. The first infusion of atezolizumab will be administered intravenously over 60 minutes. If the first infusion is tolerable, all subsequent infusions can be delivered over 30 minutes. (Atezolizumab) Prescription information, www.gene.com / download / pdf / tecentriq_prescribing.pdf.

[0087] The rapid and immediate infusion method for atezolizumab described herein was tested. Six infusion regimens were evaluated. Two infusion times were evaluated: an initial dose at 30 minutes and subsequent doses at 10 minutes. Three doses were evaluated: 840 mg, 1200 mg, and 1680 mg. To simplify the method for end-users, it is recommended to use the same infusion rate for all three test doses at the same infusion time. In this evaluation, a rate of 3 mL / min was tested for the initial 30-minute dose infusion, and a rate of 6 mL / min was tested for subsequent 10-minute dose infusions. Table 1 provides the VTBI for the three doses and two infusion times.

[0088] Table 1. Infusion rate and flushing volume

[0089]

[0090] Figure 5A and Figure 5B The graphs show the atezolizumab concentration versus time under the two different regimens. Figure 5A The illustrated scheme 1 involves infusing an 840 mg dose of atezolizumab over 30 minutes. Figure 5B Protocol 2, as shown, involves infusing an 840 mg dose of atezolizumab over 10 minutes. The concentration of atezolizumab is measured from the end of the infusion line; this is the concentration the patient is expected to experience.

[0091] Figure 6A and Figure 6B The graphs show the atezolizumab concentration versus time under the two different regimens. Figure 6A The illustrated scheme 3 involves infusing 1200 mg of atezolizumab over 30 minutes. Figure 6B Protocol 4, as shown, involves infusing a 1200 mg dose of atezolizumab over 10 minutes. The concentration of atezolizumab is measured from the end of the infusion line; this is the concentration the patient is expected to experience.

[0092] Figure 7A and Figure 7B The graphs show the atezolizumab concentration versus time under the two different regimens. Figure 7A The illustrated scheme 5 involves infusing a dose of 1680 mg of atezolizumab over 30 minutes. Figure 7B Protocol 6, as shown, involves infusing a 1680 mg dose of atezolizumab over 10 minutes. The concentration of atezolizumab is measured from the end of the infusion line, which is the concentration the patient is expected to experience.

[0093] Table 2 below summarizes six scenarios assessed during simulated infusion and saline flushing. The maximum concentration (Cmax) of atezolizumab during infusion and saline flushing ranged between 43.0 mg / mL and 57.1 mg / mL. The residual amount of atezolizumab in the infusion line after infusion (i.e., dose under-dosage) ranged from 0.5% to 4.8%. Dose under-dosage due to leaving atezolizumab in the infusion line is also applicable to current intravenous infusion bag settings and is not a risk specific to RRTI.

[0094] Table 2. Summary of simulated infusion and saline flushing

[0095]

[0096] Example 2: Load Testing

[0097] Load testing of hanger labels is performed based on or similar to DIN ISO 15137 (Self-adhesive suspension devices for infusion and injection bottles—Requirements and test methods; available on the ISO website, e.g., www.iso.org / standard / 37391.html, and incorporated herein by reference in its entirety). A permanent load test for 24 hours is performed based on / similar to DIN ISO 15137 with an adjusted weight of 500g. A short-term load test for 30 seconds is performed based on / similar to DIN ISO 15137 with an adjusted weight of 1kg. Hanger labels meet or exceed the requirements based on these tests.

[0098] Although the present disclosure described herein, including the accompanying drawings, may describe and / or illustrate different variations, it should be understood that all or part of them or their components may be combined.

[0099] Although various illustrative embodiments have been described above, any of the many changes to the various embodiments are possible. For example, in alternative embodiments, the order in which the various method steps described are performed may often be changed, while in other alternative embodiments, one or more method steps may be skipped entirely. In some embodiments, optional features of various apparatus and system embodiments may be included, while in other embodiments they may not be included. Therefore, the foregoing description is provided primarily for illustrative purposes and should not be construed as limiting the scope of the claims.

[0100] When a feature or element is referred to herein as being “on” another feature or element, it may be directly on the other feature or element, or there may be intermediate features and / or elements present. Conversely, when a feature or element is referred to as being “directly on” another feature or element, there are no intermediate features or elements present. It will also be understood that when a feature or element is referred to as being “connected,” “attached,” or “coupled” to another feature or element, it may be directly connected, attached, or coupled to the other feature or element, or there may be intermediate features or elements present. Conversely, when a feature or element is referred to as being “directly connected,” “directly attached,” or “directly coupled” to another feature or element, there are no intermediate features or elements present. Although one embodiment has been described or illustrated, the features and elements thus described or illustrated may be applied to other embodiments. References to structures or features positioned “adjacent” to another feature may have portions overlapping with or beneath the adjacent feature.

[0101] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. For example, as used herein, the singular forms “a,” “an,” and “the” are also intended to include the plural forms unless the context clearly indicates otherwise. It will also be understood that when the terms “comprises” and / or “comprising” are used in this specification, they specify the presence of the defined features, steps, operations, elements, and / or components, but do not exclude the presence or addition of one or more other features, steps, operations, elements, components, and / or groups thereof. As used herein, the term “and / or” includes any and all combinations of one or more of the associated listed items and may be abbreviated to “ / ”.

[0102] For ease of description, spatially relative terms such as “below,” “below,” “lower,” “above,” “over,” etc., may be used herein to describe the relationship of one element or feature to one or more other elements or features, as illustrated in the figures. It will be understood that, in addition to the orientations depicted in the figures, spatially relative terms are also intended to cover different orientations of the device in use or operation. For example, if the device in the figures is inverted, an element described as “below” or “under” other elements or features would be oriented as “above” other elements or features. Thus, the exemplary term “below” can include both above and below orientations. The device may be oriented in other ways (rotated 90 degrees or other orientations), and the spatially relative descriptive terms used herein shall be interpreted accordingly. Similarly, unless otherwise specifically indicated, terms such as “up,” “down,” “vertical,” “horizontal,” etc., are used herein for illustrative purposes only.

[0103] Although the terms “first” and “second” may be used herein to describe various features / elements (including steps), these features / elements should not be limited by these terms unless the context otherwise indicates. These terms may be used to distinguish one feature / element from another. Therefore, without departing from the teachings provided herein, the first feature / element discussed below may be referred to as the second feature / element, and similarly, the second feature / element discussed below may be referred to as the first feature / element.

[0104] Throughout this specification and the following claims, unless the context otherwise requires, the word “comprise” and variations such as “comprises” and “comprising” refer to a variety of components that may be used together in a method and article (e.g., a composition and an apparatus that includes means and methods). For example, the term “comprise” will be understood to imply the inclusion of any of the specified elements or steps, but does not exclude any other elements or steps.

[0105] As used herein in the specification and claims, including in the examples, and unless otherwise clearly specified, all figures may be read as beginning with the words “about” or “approximately”, even if the term is not explicitly stated. When describing magnitude and / or location, the phrases “about” or “approximately” may be used to indicate that the described value and / or location is within a reasonably expected range of value and / or location. For example, a numerical value may have values ​​of + / - 0.1%, + / - 1%, + / - 2%, + / - 5%, + / - 10%, etc., of a specified value (or range of values). In embodiments, “about” means + / - 10% or less of a specified value (or range of values). Unless the context otherwise indicates, any numerical value given herein should also be understood to include about or approximately that value.

[0106] The examples and illustrations included herein are shown in an illustrative and non-limiting manner to illustrate specific embodiments that may practice the subject matter. As mentioned, other embodiments may be utilized and derived therefrom, allowing for structural and logical substitutions and changes without departing from the scope of this disclosure. Although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may replace the specific embodiments shown. This disclosure is intended to cover any and all modifications or variations of the various embodiments. Combinations of the above embodiments and other embodiments not specifically described herein are possible.

[0107] In the foregoing description and claims, phrases such as “at least one” or “one or more” may appear, followed by a list of combinations of elements or features. The term “and / or” may also appear in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it is used, this phrase is intended to mean any element or feature listed alone, or any other recounted element or feature in combination with any other recounted element or feature. For example, the phrases “at least one of A and B”; “one or more of A and B”; and “A and / or B” are each intended to mean “A alone, B alone, or A and B together.” A similar interpretation applies to lists comprising three or more items. For example, the phrases “at least one of A and B”; “one or more of A, B, and C” and “A, B, and / or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.” The use of the term “based on” in the foregoing and claims is intended to mean “at least partially based on,” making unrecounted features or elements permissible.

[0108] The embodiments described above do not represent all embodiments consistent with the subject matter described herein. Rather, they are merely some examples consistent with aspects related to the described subject matter. Although some variations have been described in detail herein, other modifications or additions are possible. In particular, other features and / or variations may be provided in addition to those features and / or variations set forth herein. For example, the above embodiments may be applicable to various combinations and sub-combinations of the disclosed features, and / or further to combinations and sub-combinations of one or more features disclosed herein. Furthermore, the logical flows depicted in the drawings and / or described herein do not necessarily require the specific order or sequential order shown to achieve the desired results. The scope of the appended claims may include other embodiments or examples.

Claims

1. An apparatus comprising: Labels, the labels including: Back surface area; A positive surface region, which is opposite to the back surface region; and A perforation extending through the back surface region and the front surface region. A portion of the back surface area of ​​the label and the opposite portion of the front surface area of ​​the label include a movable bracket, the movable bracket causing movement from a first position to a second position, wherein the movable bracket is secured to the label at a fixed end; and In the first position, the movable bracket is at least substantially aligned with the remainder of the back surface region and the opposite remainder of the front surface region, and in the second position, the movable bracket is at least partially separated from the remainder of the back surface region and the opposite remainder of the front surface region. In this configuration, the movable hanging structure in the second position causes the bottle to be supported from the infusion rack, wherein the label is adhered to the bottle. The movable hanger is reinforced with additional support material to resist breakage and provide additional support for the bottle. The movable hanging structure in the second position supports a weight of up to 500 kg for the bottle. The perforation is located near or close to the fixed end and is curved to facilitate the movement of the movable bracket.

2. The device of claim 1, wherein the remainder of the back surface region of the label is configured to adhere to the outer side wall of the bottle.

3. The device according to claim 1 or claim 2, wherein the tag comprises a flexible material.

4. The apparatus of claim 1 or 2, wherein the back surface region comprises a portion of the back surface region and the remainder of the back surface region, and wherein the front surface region comprises the opposite portion of the front surface region and the opposite remainder of the front surface region.

5. The device according to claim 1 or 2, wherein the perforation defines at least a portion of the periphery of the movable bracket.

6. The device of claim 5, wherein the perforation is configured to at least partially separate the movable bracket from the remainder of the back surface region and the opposite remainder of the front surface region.

7. The apparatus of claim 5, wherein the movable hanging structure causes movement from the first position to the second position along the perforation.

8. The device according to any one of claims 1, 2, 6 and 7, wherein the movable bracket in the second position comprises an annular structure, the annular structure comprising two fixed ends.

9. The apparatus of claim 1, wherein the movable hanger in the second position is positioned such that the bottle is substantially suspended downwards away from the infusion rack.

10. The apparatus of claim 9, wherein the label comprises text on the front surface area, wherein the text is upside down, face up, or a combination thereof when the bottle is suspended substantially downwards.

11. The device according to any one of claims 1, 2, 6, 7, 9 and 10, wherein the length of the tag is between 75 mm and 100 mm.

12. The device according to any one of claims 1, 2, 6, 7, 9 and 10, wherein the height of the label is between 30 mm and 40 mm.

13. The device according to any one of claims 1, 2, 6, 7, 9 and 10, wherein the width of the movable bracket is between 5 mm and 7 mm.

14. A method comprising: The first volume of saline solution was infused into the infusion pipeline via an infusion pump. Remove the cap from a bottle containing medicine, wherein the bottle includes a stopper at its top, and further, wherein the cap is configured to cover the stopper; The plug is pierced with an infusion line puncture needle located near the end of the infusion line; The label attached to the bottle opens the movable hanger into a ring configuration, wherein the movable hanger is formed by a portion of the label and configured to move from a closed configuration into the ring configuration; as well as The bottle is suspended from the infusion rack via the movable bracket. The label includes: a back surface area; a front surface area opposite to the back surface area; and a perforation extending through the back surface area and the front surface area. The movable hanger is reinforced with additional support material to resist breakage and provide additional support for the bottle. The movable hanging structure supports a weight of up to 500 kg for the bottle. The movable bracket is fixed to the label at the fixed end of the label, and the perforation is adjacent to or near the fixed end and is curved to facilitate the movement of the movable bracket.

15. The method of claim 14, further comprising: Open the vent cap on the infusion line needle; as well as On the infusion pump, an infusion rate and infusion volume are set for the drug to be administered to the patient, wherein the drug travels from the bottle through the infusion line via a needle to a needle inserted into the patient's body, wherein the needle is positioned at the distal end of the infusion line, and further, wherein the infusion pump is connected to the infusion line to pump the drug at the infusion rate.

16. The method of claim 15, further comprising: A second drug is administered to the patient via the infusion pump and upon completion of the administration of the drug to the patient, wherein the second drug may be of the same or different type as the drug.

17. The method according to claim 15 or claim 16, further comprising: A second volume of saline solution is infused into the infusion line via the infusion pump.

18. The method of claim 17, wherein after the second amount of saline is infused at an infusion rate of 3 mL / min for 30 minutes, less than 1.5% of the initial amount of the drug remains in the infusion line, wherein the infusion time includes the drug administration time and the second saline flushing time.

19. The method of claim 17, wherein after the second amount of saline is infused at an infusion rate of 6 mL / min for 10 minutes, less than 5% of the initial amount of the drug remains in the infusion line, wherein the infusion time includes the drug administration time and the second saline flushing time.

20. The method according to any one of claims 14-16, wherein the movable hanger is formed by a portion of the back surface region of the label and the opposite portion of the front surface region.

21. The method of claim 20, wherein the perforation defines at least a portion of the periphery of the movable bracket.

22. The method of claim 21, wherein the perforation is configured such that the movable hanger opens from the closed configuration to the annular configuration.

23. The method according to any one of claims 14-16, 21 and 22, wherein the drug is not diluted before administration.

24. The method according to any one of claims 14-16, 21 and 22, wherein the initial amount of the drug in the bottle is less than 30 mL.

25. A method of administering a drug to a patient in need, comprising: (a) The first volume of normal saline is infused into the patient via the infusion line; (b) Infusing a predetermined volume of the drug from a vial into the patient via the infusion line for a first time period, wherein the initial volume of the drug in the vial is less than or equal to 30 mL and is not diluted prior to infusion into the patient; and (c) A second volume of normal saline is infused into the patient via the infusion line for a second time period; After the second volume of saline is infused, less than 5% of the initial dose of the drug remains in the infusion line. The bottle is supported from the dispensing rack by a movable tag holder, wherein the tag is adhered to the bottle; The label includes: a back surface area; a front surface area opposite to the back surface area; and a perforation extending through the back surface area and the front surface area. The movable hanger is reinforced with additional support material to resist breakage and provide additional support for the bottle. The movable hanging structure supports a weight of up to 500 kg for the bottle. The movable bracket portion is fixed to the label at the fixed end of the label, and the perforation is adjacent to or close to the fixed end and is curved to facilitate the movement of the movable bracket.

26. The method of claim 25, wherein the drug is administered at a fixed dose.

27. The method according to claim 25 or 26, wherein the initial amount of the drug in the bottle is less than or equal to 10 mL.

28. The method according to claim 25 or 26, wherein the sum of the first time period and the second time period is less than or equal to 60 minutes.

29. The method of claim 28, wherein the sum of the first time period and the second time period is less than or equal to 30 minutes.

30. The method of claim 28, wherein the sum of the first time period and the second time period is less than or equal to 15 minutes.

31. The method according to any one of claims 25, 26, 29 and 30, wherein after infusion of the second amount of saline, less than 1.5% of the initial amount of the drug remains in the infusion line.

32. The method according to any one of claims 25, 26, 29 and 30, wherein the infusion volume of the drug is between 10 mL and 30 mL and the second volume of physiological saline is between 25 mL and 90 mL.

33. The method according to any one of claims 25, 26, 29 and 30, wherein the drug and the second amount of physiological saline are infused into the patient at an infusion rate between 1 mL / min and 10 mL / min.

Images